Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cardiol Therapeutics Inc Class A (CRDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CRDL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.85
1 Year Target Price $8.85
| 1 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.34% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.38M USD | Price to earnings Ratio - | 1Y Target Price 8.85 |
Price to earnings Ratio - | 1Y Target Price 8.85 | ||
Volume (30-day avg) 5 | Beta 0.61 | 52 Weeks Range 0.77 - 2.54 | Updated Date 09/14/2025 |
52 Weeks Range 0.77 - 2.54 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Earnings Date
Report Date 2025-08-19 | When - | Estimate -0.0997 | Actual -0.0722 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -108.74% | Return on Equity (TTM) -276.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78329840 | Price to Sales(TTM) 1069.35 |
Enterprise Value 78329840 | Price to Sales(TTM) 1069.35 | ||
Enterprise Value to Revenue 178.81 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 83729400 | Shares Floating 80679184 |
Shares Outstanding 83729400 | Shares Floating 80679184 | ||
Percent Insiders 4.18 | Percent Institutions 8.31 |
Upturn AI SWOT
Cardiol Therapeutics Inc Class A
Company Overview
History and Background
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for inflammatory heart disease. Founded in 2016, it has focused on developing pharmaceutical cannabidiol formulations for various cardiovascular conditions.
Core Business Areas
- Inflammatory Heart Disease Therapeutics: Development of pharmaceutical cannabidiol formulations (e.g., CardiolRx) for treating acute myocarditis and recurrent pericarditis.
Leadership and Structure
The company is led by CEO David Elsley. The organizational structure includes departments for research and development, clinical operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- CardiolRx: A pharmaceutically produced cannabidiol formulation being investigated for its anti-inflammatory and anti-fibrotic properties in cardiovascular disease. It is currently in clinical trials for acute myocarditis and recurrent pericarditis. There is no current Market Share since it is not yet approved for market. Competitors are standard of care treatments such as NSAIDs and colchicine.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on cardiovascular disease is competitive and rapidly evolving. There is increasing demand for novel therapeutics to treat inflammatory heart conditions.
Positioning
Cardiol Therapeutics is positioned as a developer of novel cannabidiol-based therapeutics for inflammatory heart disease, targeting unmet medical needs with a unique approach.
Total Addressable Market (TAM)
The TAM for inflammatory heart disease therapeutics is significant, estimated in the billions of dollars annually. Cardiol is positioned to capture a portion of this market with successful development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel cannabidiol-based therapeutic approach
- Focus on unmet medical needs in inflammatory heart disease
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on single lead product candidate (CardiolRx)
- Limited commercialization experience
- High cash burn rate
- Clinical trial risks and regulatory hurdles
Opportunities
- Successful clinical trial results and regulatory approval
- Expansion of product pipeline to address other cardiovascular conditions
- Partnerships with larger pharmaceutical companies
- Growing acceptance of cannabidiol-based therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory challenges and changes
- Negative perception of cannabidiol-based therapies
Competitors and Market Share
Key Competitors
- Bayer (BAYRY)
- Novartis (NVS)
- Bristol-Myers Squibb (BMY)
Competitive Landscape
Cardiol Therapeutics faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Cardiol's competitive advantage lies in its focus on novel cannabidiol-based therapeutics for inflammatory heart disease.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily based on clinical trial progress and securing funding for development.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of CardiolRx.
Recent Initiatives: Focus on clinical trials for CardiolRx in acute myocarditis and recurrent pericarditis.
Summary
Cardiol Therapeutics is a clinical-stage biotech company with a novel approach to treating inflammatory heart disease. Its success hinges on positive clinical trial outcomes for CardiolRx. While facing competition and financial risks, the company has significant opportunities in a growing market. Overall, it is a speculative investment with high potential but also high risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on available information and may be subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiol Therapeutics Inc Class A
Exchange NASDAQ | Headquaters Oakville, ON, Canada | ||
IPO Launch date 2019-01-15 | President, CEO & Director Mr. David G. Elsley MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 18 | Website https://www.cardiolrx.com |
Full time employees 18 | Website https://www.cardiolrx.com | ||
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.